Table 1. Comparison of clinical characteristics according to eGFR ≧ or < 60 min/ml/1.73m2.
| Characteristics | eGFR ≧ 60 min/ml/1.73m2 (n = 6425) | eGFR < 60 min/ml/1.73m2 (n = 1834) | All (n = 8259) | p |
|---|---|---|---|---|
| Age (year) | 60.3 ± 11.4 | 68.6 ± 10.9 | 62.0 ± 11.9 | < 0.001 |
| Male gender (%) | 51.5 | 54.0 | 52.0 | 0.056 |
| Hypertension (%) | 69.4 | 84.9 | 72.8 | < 0.001 |
| Dyslipidemia (%) | 71.4 | 61.8 | 69.3 | < 0.001 |
| Retinopathy (%) | 3.6 | 11.4 | 5.3 | < 0.001 |
| Neuropathy (%) | 12.2 | 17.4 | 13.4 | < 0.001 |
| Nephropathy (%) | 3.9 | 10.7 | 5.4 | < 0.001 |
| DM duration > 5 years (%) | 91.7 | 92.6 | 91.9 | 0.215 |
| Laboratory parameters | ||||
| SD HbA1C (%) | 0.81 ± 0.56 | 0.93 ± 0.65 | 0.84 ± 0.58 | < 0.001 |
| Mean HbA1C (%) | 7.5 ± 1.2 | 7.4 ± 1.2 | 7.5 ± 1.2 | 0.017 |
| Triglyceride (mg/dL) | 146.7 ± 136.8 | 161.6 ± 114.3 | 154.7 ± 206.0 | < 0.001 |
| Total cholesterol (mg/dL) | w176.8 ± 41.0 | 181.0 ± 48.1 | 178.2 ± 44.9 | 0.001 |
| HDL-cholesterol (mg/dL) | 41.3 ± 12.4 | 38.6 ± 12.4 | 40.7 ± 12.5 | < 0.001 |
| LDL-cholesterol (mg/dL) | 102.8 ± 33.1 | 102.2 ± 36.3 | 102.6 ± 34.0 | 0.578 |
| eGFR (mL/min/1.73 m2) | 96.0 ± 23.5 | 39.9 ± 14.8 | 84.5 ± 35.4 | < 0.001 |
| Medications | ||||
| ACEI and/or ARB use (%) | 62.8 | 80.5 | 66.6 | < 0.001 |
| Aspirin use (%) | 29.1 | 42.7 | 32.1 | < 0.001 |
| Statin and/or fibrate use (%) | 69.6 | 70.8 | 69.9 | 0.341 |
| Insulin use (%) | 18.1 | 35.3 | 22.1 | < 0.001 |
| Days of follow-up (days) | 2330.4 ± 426.7 | 2165.6 ± 650.1 | 2294.3 ± 489.1 | < 0.001 |
| CV events (%) | 6.5 | 17.6 | 8.9 | < 0.001 |
Abbreviations. eGFR, estimated glomerular filtration rate; DM, diabetes mellitus; SD, standard deviation; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CV, cardiovascular.